← SynDRA
ATAMPARIB
SynDRA canonical compound SYN0040356 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
| Primary target(s) | TIPARP |
| Mechanism of action | parp inhibitor |
| Indication | carcinoid tumors |
| Disease area | oncology |
All known targets
Mechanisms of action (all sources)
- PARP inhibitor
- TIPARP INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- CYP2C9
- PARP3
- TNKS2
- PARP11
- PARP12
- PARP14
- PARP2
- PARP1
- PARP4
- PARP16
- ABL1
- PARP6
- PARP8
- PARP9
- STAT1
- TNKS
- PARP10
- MAPK1
- AURKA
- HDAC6
- HDAC1
- GSK3B
- FGFR3
- FGFR2
- CYP3A4
- CYP2D6
- CYP2C19
- CYP1A2
- CSNK1D
- CDK2
- BRPF1
- BRD4
- TRIM24
Cross-references
Synonyms
- RBN-2397
- ATAMPARIB (RBN-2397)
- RBN2397
- Atamparib [INN]
- UNII-B1MW2ME77A
- B1MW2ME77A
- SCHEMBL21521281
- BCP33764
- EX-A4038
- RBN2397;RBN 2397
- NSC825956
- s8993
- NSC-825956
- HY-136174
- CS-0120272
- 3(2H)-Pyridazinone, 5-(((1S)-1-methyl-2-(3-oxo-3-(4-(5-(trifluoromethyl)-2-pyrimidinyl)-1-piperazinyl)propoxy)ethyl)amino)-4-(trifluoromethyl)-
- 5-(((2S)-1-(3-Oxo-3-(4-(5-(trifluoromethyl)pyrimidin-2- yl)piperazin-1-yl)propoxy)propan-2-yl)amino)-4- (trifluoromethyl)pyridazin-3(2H)-one
- Rbn 2397
- RefChem:115402
- PARP7 Inhibitor RBN-2397
- Atamparib [USAN]
- Atamparib [WHO-DD]
- Atamparib (USAN/INN)
- Atamparib [USAN:INN]
- orb1309170
- GTPL13118
- C20H23F6N7O3
- UQZCQKXJAXKZQH-LBPRGKRZSA-N
- BDBM431795
- GLXC-26409
- MFCD32701939
- WHO 11539
- AKOS040736567
- EBC-419041
- NCGC00842088-01
- AC-36483
- AS-76787
- DA-67127
- SY278680
Look up ATAMPARIB in the interactive SynDRA portal →